A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Perhexiline (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Sponsors Heart Metabolics Limited
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2017 Status changed from recruiting to discontinued.
- 16 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.